Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCZFMS)

Drug Name

ABX-IL8 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-8 (IL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[3]
BMS-986253	DM42B0C	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
MDX-018	DML5FX2	Autoimmune diabetes	5A10	Phase 1	[5]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[3]
2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid	DM54M6C	Discovery agent	N.A.	Investigative	[3]
2-(2-(2-chlorophenylamino)phenyl)acetic acid	DMPLV3A	Discovery agent	N.A.	Investigative	[3]
2-(2-(2-fluorophenylamino)phenyl)acetic acid	DMVQ68F	Discovery agent	N.A.	Investigative	[3]
2-(2-(2-chlorophenoxy)phenyl)acetic acid	DMBP1TQ	Discovery agent	N.A.	Investigative	[3]
2-(2-(2-fluorophenoxy)phenyl)acetic acid	DMDSUR2	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00035828) A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD. U.S. National Institutes of Health.
2	Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
3	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
4	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
5	Company report (Genmab)